New RSV drug delivers promising results in Alaska’s Yukon-Kuskokwim Delta
A recently approved immunization drug is helping to limit the severity of a respiratory disease that afflicts young children ...
Too Old to Operate7h
Understanding Parental Decision-Making for Nirsevimab in RSV Prevention
The following is a summary of “Parent Perspectives on Nirsevimab for Their Newborn,” published in the November 2024 issue of ...
What are the options for protecting babies from RSV?
RSV is the most common cause of hospitalization in infants under 1 year old. The infection can spread to the lungs and cause ...
The Lancet4d
Highlights of IDWeek 2024
IDWeek 2024 was held at the Los Angeles Convention Center in Downtown Los Angeles, CA, USA, from 16–19 October. Phoebe Hall ...
Monthly Prescribing Reference6d
Studies Examine Cost-Effectiveness of Maternal RSV Vaccination, Nirsevimab in Infants
Seasonal maternal RSV vaccination may be cost-effective, as well as nirsevimab, particularly for those with higher risks ...
Studies examine cost-effectiveness of maternal RSV vaccination and nirsevimab in infants
Seasonal maternal respiratory syncytial virus (RSV) vaccination and nirsevimab for infants demonstrate cost-effectiveness, according to two studies published online Nov. 25 in Pediatrics.
cidrap.umn6d
RSV prevention tools somewhat cost-effective, studies show
University of Michigan and Centers for Disease Control and Prevention (CDC) investigators determined that both maternal ...
denipt6d
Free RSV protection plan
Infants will be able to receive a free immunisation to protect them against serious illness from respiratory syncytial virus (RSV), under a new $16.6 million NSW ...